Characteristics of infused T-cell products
| Patient no. . | Expansion after transduction, d . | Expansion after transduction, fold . | CAR transduction . | Cytotoxicity at 20:1 . | VCN per transduced cell . | Viability . | Frequency of CD4+ . | Daily expansion, fold . |
|---|---|---|---|---|---|---|---|---|
| 2 | 7 | 133.3 | 97.6% | 85.60% | 6.8 | 97.00% | 8.98% | 19.0 |
| 3 | 4 | 21.0 | 99.1% | 51.80% | 4.6 | 96.90% | 55.99% | 5.3 |
| 5 | 4 | 9.2 | 98.4% | 50.50% | 7.71 | 85.90% | 50.44% | 2.3 |
| 6 | 4 | 23.4 | 98.6% | 59.80% | 6.08 | 89.40% | 57.28% | 5.9 |
| 14 | 5 | 36.2 | 98.6% | 65.70% | 1.81 | 92.50% | 52.99% | 7.2 |
| 23 | 6 | 24.5 | 96.9% | 87.60% | 3.73 | 95.70% | 30.03% | 4.1 |
| 28 | 4 | 14.5 | 98.3% | 52.90% | 2.36 | 93.30% | 9.93% | 3.6 |
| 31 | 6 | 23.6 | 98.8% | 72.20% | 4.9 | 95.80% | 60.33% | 3.9 |
| 32 | 5 | 13.9 | 98.7% | 43.40% | 1.62 | 94.60% | 52.88% | 2.8 |
| Patient no. . | Expansion after transduction, d . | Expansion after transduction, fold . | CAR transduction . | Cytotoxicity at 20:1 . | VCN per transduced cell . | Viability . | Frequency of CD4+ . | Daily expansion, fold . |
|---|---|---|---|---|---|---|---|---|
| 2 | 7 | 133.3 | 97.6% | 85.60% | 6.8 | 97.00% | 8.98% | 19.0 |
| 3 | 4 | 21.0 | 99.1% | 51.80% | 4.6 | 96.90% | 55.99% | 5.3 |
| 5 | 4 | 9.2 | 98.4% | 50.50% | 7.71 | 85.90% | 50.44% | 2.3 |
| 6 | 4 | 23.4 | 98.6% | 59.80% | 6.08 | 89.40% | 57.28% | 5.9 |
| 14 | 5 | 36.2 | 98.6% | 65.70% | 1.81 | 92.50% | 52.99% | 7.2 |
| 23 | 6 | 24.5 | 96.9% | 87.60% | 3.73 | 95.70% | 30.03% | 4.1 |
| 28 | 4 | 14.5 | 98.3% | 52.90% | 2.36 | 93.30% | 9.93% | 3.6 |
| 31 | 6 | 23.6 | 98.8% | 72.20% | 4.9 | 95.80% | 60.33% | 3.9 |
| 32 | 5 | 13.9 | 98.7% | 43.40% | 1.62 | 94.60% | 52.88% | 2.8 |